BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 37467061)

  • 21. Mutations in GNA11 in uveal melanoma.
    Van Raamsdonk CD; Griewank KG; Crosby MB; Garrido MC; Vemula S; Wiesner T; Obenauf AC; Wackernagel W; Green G; Bouvier N; Sozen MM; Baimukanova G; Roy R; Heguy A; Dolgalev I; Khanin R; Busam K; Speicher MR; O'Brien J; Bastian BC
    N Engl J Med; 2010 Dec; 363(23):2191-9. PubMed ID: 21083380
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Combined Inhibition of Gα
    Hitchman TD; Bayshtok G; Ceraudo E; Moore AR; Lee C; Jia R; Wang N; Pachai MR; Shoushtari AN; Francis JH; Guan Y; Chen J; Chang MT; Taylor BS; Sakmar TP; Huber T; Chi P; Chen Y
    Clin Cancer Res; 2021 Mar; 27(5):1476-1490. PubMed ID: 33229459
    [TBL] [Abstract][Full Text] [Related]  

  • 23. RasGRP3 Mediates MAPK Pathway Activation in GNAQ Mutant Uveal Melanoma.
    Chen X; Wu Q; Depeille P; Chen P; Thornton S; Kalirai H; Coupland SE; Roose JP; Bastian BC
    Cancer Cell; 2017 May; 31(5):685-696.e6. PubMed ID: 28486107
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Protein kinase inhibitor responses in uveal melanoma reflects a diminished dependency on PKC-MAPK signaling.
    Park JJ; Stewart A; Irvine M; Pedersen B; Ming Z; Carlino MS; Diefenbach RJ; Rizos H
    Cancer Gene Ther; 2022 Oct; 29(10):1384-1393. PubMed ID: 35352024
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Chloroquine Sensitizes
    Truong A; Yoo JH; Scherzer MT; Sanchez JMS; Dale KJ; Kinsey CG; Richards JR; Shin D; Ghazi PC; Onken MD; Blumer KJ; Odelberg SJ; McMahon M
    Clin Cancer Res; 2020 Dec; 26(23):6374-6386. PubMed ID: 32933997
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Protein kinase C inhibitors sensitize GNAQ mutant uveal melanoma cells to ionizing radiation.
    Cerne JZ; Hartig SM; Hamilton MP; Chew SA; Mitsiades N; Poulaki V; McGuire SE
    Invest Ophthalmol Vis Sci; 2014 Apr; 55(4):2130-9. PubMed ID: 24595385
    [TBL] [Abstract][Full Text] [Related]  

  • 27. GNAQ and GNA11 mutant nonuveal melanoma: a subtype distinct from both cutaneous and uveal melanoma.
    Livingstone E; Zaremba A; Horn S; Ugurel S; Casalini B; Schlaak M; Hassel JC; Herbst R; Utikal JS; Weide B; Gutzmer R; Meier F; Koelsche C; Hadaschik E; Sucker A; Reis H; Merkelbach-Bruse S; Siewert M; Sahm F; von Deimling A; Cosgarea I; Zimmer L; Schadendorf D; Schilling B; Griewank KG
    Br J Dermatol; 2020 Nov; 183(5):928-939. PubMed ID: 32064597
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prognostic impact of chromosomal aberrations and GNAQ, GNA11 and BAP1 mutations in uveal melanoma.
    Staby KM; Gravdal K; Mørk SJ; Heegaard S; Vintermyr OK; Krohn J
    Acta Ophthalmol; 2018 Feb; 96(1):31-38. PubMed ID: 28444874
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Frequent and Yet Unreported GNAQ and GNA11 Mutations are Found in Uveal Melanomas.
    Schneider B; Riedel K; Zhivov A; Huehns M; Zettl H; Guthoff RF; Jünemann A; Erbersdobler A; Zimpfer A
    Pathol Oncol Res; 2019 Oct; 25(4):1319-1325. PubMed ID: 29209985
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Kinome profiling identifies MARK3 and STK10 as potential therapeutic targets in uveal melanoma.
    Baqai U; Kurimchak AM; Trachtenberg IV; Purwin TJ; Haj JI; Han A; Luo K; Pachon NF; Jeon A; Chua V; Davies MA; Gutkind JS; Benovic JL; Duncan JS; Aplin AE
    J Biol Chem; 2023 Dec; 299(12):105418. PubMed ID: 37923138
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Functional characterization of uveal melanoma oncogenes.
    Ma J; Weng L; Bastian BC; Chen X
    Oncogene; 2021 Jan; 40(4):806-820. PubMed ID: 33262460
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Skin metastases in metastatic uveal melanoma: GNAQ/GNA11 mutational analysis as a valuable tool.
    Tsianakas A; Böhm MR; Getova V; Metze D; Eter N; Spieker T; Bräuninger A; Luger T; Schiller M; Sunderkötter C
    Br J Dermatol; 2013 Jul; 169(1):160-3. PubMed ID: 23464620
    [TBL] [Abstract][Full Text] [Related]  

  • 33. GNAQ and GNA11 mutations in uveal melanoma.
    Shoushtari AN; Carvajal RD
    Melanoma Res; 2014 Dec; 24(6):525-34. PubMed ID: 25304237
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Oncogenic GNAQ and GNA11 mutations in uveal melanoma in Chinese.
    Xu X; Wei WB; Li B; Gao F; Zhang Z; Jonas JB
    PLoS One; 2014; 9(10):e109699. PubMed ID: 25280020
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mutant GNAQ promotes cell viability and migration of uveal melanoma cells through the activation of Notch signaling.
    Liu H; Lei C; Long K; Yang X; Zhu Z; Zhang L; Liu J
    Oncol Rep; 2015 Jul; 34(1):295-301. PubMed ID: 25955651
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dual Inhibition of Histone Deacetylases and the Mechanistic Target of Rapamycin Promotes Apoptosis in Cell Line Models of Uveal Melanoma.
    Patel RP; Thomas JR; Curt KM; Fitzsimmons CM; Batista PJ; Bates SE; Gottesman MM; Robey RW
    Invest Ophthalmol Vis Sci; 2021 Sep; 62(12):16. PubMed ID: 34533562
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Direct targeting of Gα
    Annala S; Feng X; Shridhar N; Eryilmaz F; Patt J; Yang J; Pfeil EM; Cervantes-Villagrana RD; Inoue A; Häberlein F; Slodczyk T; Reher R; Kehraus S; Monteleone S; Schrage R; Heycke N; Rick U; Engel S; Pfeifer A; Kolb P; König G; Bünemann M; Tüting T; Vázquez-Prado J; Gutkind JS; Gaffal E; Kostenis E
    Sci Signal; 2019 Mar; 12(573):. PubMed ID: 30890659
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Heterogeneity in Mitogen-Activated Protein Kinase (MAPK) Pathway Activation in Uveal Melanoma With Somatic GNAQ and GNA11 Mutations.
    Boru G; Cebulla CM; Sample KM; Massengill JB; Davidorf FH; Abdel-Rahman MH
    Invest Ophthalmol Vis Sci; 2019 Jun; 60(7):2474-2480. PubMed ID: 31173078
    [TBL] [Abstract][Full Text] [Related]  

  • 39. IGF1R Inhibition Enhances the Therapeutic Effects of Gq/11 Inhibition in Metastatic Uveal Melanoma Progression.
    Lapadula D; Lam B; Terai M; Sugase T; Tanaka R; Farias E; Kadamb R; Lopez-Anton M; Heine CC; Modasia B; Aguirre-Ghiso JA; Aplin AE; Sato T; Benovic JL
    Mol Cancer Ther; 2023 Jan; 22(1):63-74. PubMed ID: 36223548
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Targeting the YAP/TAZ Pathway in Uveal and Conjunctival Melanoma With Verteporfin.
    Brouwer NJ; Konstantinou EK; Gragoudas ES; Marinkovic M; Luyten GPM; Kim IK; Jager MJ; Vavvas DG
    Invest Ophthalmol Vis Sci; 2021 Apr; 62(4):3. PubMed ID: 33798262
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.